As a result, numerous studies have embarked on the journey to unravel the genetic factors and oncogenic pathways at the core of mesothelioma, all in pursuit of discovering fresh avenues for therapeutic intervention.4, 5, 6 Recently, small series of mesothelioma, mostly from the peritoneum, were reported to be driven by recurrent gene fusions, such as EWSR1/FUS-CREB, YY1, MAP3K8, NR4A3 and ALK fusions,7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 but most often with no specific clinical or histological features. This evidence concerns the gene YY1 and mesothelioma.